salicylsalicylic acid has been researched along with Aging in 2 studies
salicylsalicylic acid: structure
salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jablonski, KL | 1 |
| Donato, AJ | 1 |
| Fleenor, BS | 1 |
| Nowlan, MJ | 1 |
| Walker, AE | 1 |
| Kaplon, RE | 1 |
| Ballak, DB | 1 |
| Seals, DR | 2 |
| Pierce, GL | 1 |
| Lesniewski, LA | 1 |
| Lawson, BR | 1 |
| Beske, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Nebivolol on Microvascular Perfusion in the Skeletal Muscles During Exercise in Hypertensive Patients[NCT01501929] | Phase 4 | 32 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Targeting Inflammation to Treat Cardiovascular Aging in Humans (TIVA Study)[NCT01775865] | Phase 2 | 59 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach[NCT01398943] | 60 participants (Actual) | Interventional | 2010-09-30 | Completed | |||
| Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System[NCT03109795] | Phase 4 | 30 participants (Actual) | Interventional | 2017-04-10 | Terminated (stopped due to Funding ended) | ||
| The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study[NCT03222206] | Phase 4 | 34 participants (Actual) | Interventional | 2017-11-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Endothelial cell (EC) was collected after a 20-guage angiocatheter was inserted into the contralateral forearm vein under sterile conditions. Three J-shaped vascular guidewires (St. Jude, St. Paul, MN) were advanced sequentially into the vein up to 10 cm. Endothelial cells were collected by gentle abrasion and placed into a dissociation buffer (0.5% bovine serum albumin, 2mM EDTA, and 100 ug/ml heparin in PBS). Endothelial cells were recovered from the tips of guide wires by repeated washing into collection tubes and subsequent centrifugation. EC were incubated with monoclonal antibodies against the polyclonal antibodies against NADPH oxidase p47 subunit. The intensity of staining was measured using fluorescence microscopy. (NCT01501929)
Timeframe: 12 weeks
| Intervention | Ratio human to HUVEC p47Phox expression (Mean) |
|---|---|
| Metoprolol | 0.47 |
| Nebivolol | 0.44 |
Microvascular perfusion of skeletal muscle were measured during handgrip at 20 cycle per minute after 12 weeks of metoprolol, and after 12 weeks of nebivolol (NCT01501929)
Timeframe: 12 weeks
| Intervention | video intensity units/ second (Median) |
|---|---|
| Metoprolol | 43.938 |
| Nebivolol | 74.584 |
Endothelial function (NCT01775865)
Timeframe: Change from baseline brachial artery FMD at 4 weeks
| Intervention | Percent dilation (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| Placebo | 3.57 | 2.50 |
| Salsalate | 3.49 | 4.60 |
| Young Control Group | 5.88 | NA |
Aortic stiffness (NCT01775865)
Timeframe: Change in CFPWV from baseline at 4 weeks
| Intervention | cm/sec (Mean) | |
|---|---|---|
| Baseline | 4 weeks | |
| Placebo | 785.1 | 740.01 |
| Salsalate | 831.3 | 839.6 |
| Young Control Group | 538.0 | NA |
Brachial artery FMD induced by reactive hyperemia will be used to assess vascular endothelial function at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post FMD was taken approximately 110 min after baseline
| Intervention | percentage of change in FMD (Mean) | |
|---|---|---|
| Placebo | AOC Treatment | |
| All Controls | 6.7 | 6.9 |
| All COPD Patients | 3.1 | 4.7 |
A measure of vascular stiffness at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post PWV was taken approximately 90 min after baseline
| Intervention | m/sec (Mean) | |
|---|---|---|
| Placebo | AOC Treatment | |
| All Controls | 11 | 10 |
| All COPD Patients | 14 | 11 |
2 trials available for salicylsalicylic acid and Aging
| Article | Year |
|---|---|
Reduced large elastic artery stiffness with regular aerobic exercise in middle-aged and older adults: potential role of suppressed nuclear factor κ B signalling.
Topics: Aging; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Blood Pressure; Cardiovascular Diseases; Cros | 2015 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |
Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans.
Topics: Administration, Oral; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Body Mass Index; Cross-O | 2009 |